Cleveland BioLabs (CBLI) has a profit margin of -6043.51%, below the Healthcare sector average of 19.13%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2021
Trailing 12 months ending Jun 2021
As of the most recent data (June 2021), CBLI shows a profit margin of -6043.51%. That compares with -246.62% in the prior-year period — down 2350.5% year over year. That is below the Healthcare sector average of 19.13%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CBLI's profit margin is now -6043.51% (was -246.62%) — a 2350.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cleveland BioLabs is outperforming or lagging.
The Healthcare sector average profit margin is about 19.13%. Cleveland BioLabs is at -6043.51%, which is lower that average. That is roughly 31689.7% below the sector mean. Use the comparison chart on this page to see how CBLI stacks up against individual peers as well.
That compares with -246.62% in the prior-year period — down 2350.5% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Cleveland BioLabs with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has Cleveland BioLabs's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -6043.51%) with ownership activity and broader fundamentals.